Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Some statements match the provided label excerpts (e.g., obesity/weight indication, severe GI reactions, MTC/MEN2 contraindications, heart rate increase counseling). However, several key safety claims are unsupported or conflict with the provided label (e.g., “help lower blood sugar,” “not recommended for history of pancreatic disease,” “not recommended for thyroid cancer/MTC family history” wording), and multiple adverse-event percentage claims are not supported by the provided label text.
Category Scores
Accurate Statements
Wegovy is a prescription medication containing semaglutide.
11 DESCRIPTION: “WEGOVY contains semaglutide…”
Wegovy is used to treat obesity along with diet and exercise.
1 INDICATIONS AND USAGE: “WEGOVY injection/tablets are indicated in combination with a reduced calorie diet and increased physical activity… to reduce excess body weight and maintain weight reduction long term… adults… with obesity; and pediatric patients aged 12 years and older with obesity.”
Nausea occurred in 34.4% of patients in clinical trials of Wegovy.
Vomiting occurred in 21.4% of patients in clinical trials of Wegovy.
Diarrhea occurred in 24.8% of patients in clinical trials of Wegovy.
Abdominal pain occurred in 16% of patients in clinical trials of Wegovy.
Injection site reactions occurred in 10.4% of patients in clinical trials of Wegovy.
Headache occurred in 14.6% of patients in clinical trials of Wegovy.
Fatigue occurred in 10.7% of patients in clinical trials of Wegovy.
Wegovy may cause increased heart rate.
17 Patient Counseling Information: “Heart Rate Increase… inform their healthcare providers of palpitations or feelings of a racing heartbeat…” [5.9]
Wegovy may cause pancreatitis (inflammation of the pancreas).
17 Patient Counseling Information: “Acute Pancreatitis… potential risk for acute pancreatitis…”
Wegovy helps lower blood sugar levels.
Unsupported Statements
Wegovy works by mimicking a naturally occurring hormone in the body that helps regulate appetite.
The provided label excerpts do not describe this mechanism in those terms.
Wegovy helps lower blood sugar levels.
No provided label excerpt states that WEGOVY lowers blood sugar levels.
Nausea occurred in 34.4% of patients in clinical trials of Wegovy.
No provided label excerpt includes these specific percentage values.
Vomiting occurred in 21.4% of patients in clinical trials of Wegovy.
No provided label excerpt includes these specific percentage values.
Diarrhea occurred in 24.8% of patients in clinical trials of Wegovy.
No provided label excerpt includes these specific percentage values.
Abdominal pain occurred in 16% of patients in clinical trials of Wegovy.
No provided label excerpt includes these specific percentage values.
Injection site reactions occurred in 10.4% of patients in clinical trials of Wegovy.
No provided label excerpt includes these specific percentage values.
Headache occurred in 14.6% of patients in clinical trials of Wegovy.
No provided label excerpt includes these specific percentage values.
Fatigue occurred in 10.7% of patients in clinical trials of Wegovy.
No provided label excerpt includes these specific percentage values.
Wegovy may cause thigh or leg pain (possibly due to reduced blood flow).
The provided label excerpts do not mention thigh/leg pain or the suggested mechanism (reduced blood flow).
Wegovy may cause kidney problems.
The provided label excerpt discusses “Acute Kidney Injury due to Volume Depletion” and counseling to avoid dehydration, but the claim “may cause kidney problems” is broader and not directly supported as stated.
Wegovy is not recommended for people with a history of pancreatic disease.
The provided label excerpts do not include a “not recommended” restriction for history of pancreatic disease. They discuss counseling about acute pancreatitis risk/symptoms.
Wegovy is not recommended for people with a thyroid cancer.
The provided label excerpt contains a boxed-warning-adjacent counseling section about thyroid C-cell tumors and contraindication related to MTC/MEN2, but it does not state “not recommended” for thyroid cancer.
Wegovy is not recommended for people with a personal or family history of medullary thyroid carcinoma.
The provided label excerpt states contraindication for personal or family history of MTC or MEN 2, not “not recommended.” This is not supported as written.
In a clinical trial of 2,254 patients, serious adverse reactions occurred in 2.9% of patients taking semaglutide.
No provided label excerpt includes these study size and percentage values for serious adverse reactions.
In the same clinical trial, serious adverse reactions occurred in 1.1% of patients taking placebo.
No provided label excerpt includes these study size and percentage values for serious adverse reactions.
People taking Wegovy should monitor their blood sugar levels closely.
The provided label excerpts mention hypoglycemia risk counseling for patients with diabetes on glycemic lowering therapy, but do not state “monitor their blood sugar levels closely” as written for general users.
People taking Wegovy should seek immediate medical attention if they experience signs of pancreatitis or other serious side effects.
The provided label excerpts instruct patients to discontinue and contact their physician if pancreatitis is suspected, but do not state “immediate medical attention” or “other serious side effects” generally.
Contradictions
Low
AI Statement
Wegovy is not recommended for people with a thyroid cancer.
Label Reference
4 CONTRAINDICATIONS: contraindicated for personal/family history of MTC or MEN 2; no provided label excerpt states “not recommended for thyroid cancer.”
Important Omissions
Dose/administration details (e.g., titration, missed dose instructions, route).
Importance:
Moderate
Contraindication specifics for semaglutide or excipient hypersensitivity and MEN 2/MTC wording exactly as contraindications.
Importance:
Moderate
Key warnings/precautions present in provided label excerpts, such as severe gastrointestinal adverse reactions percentages by formulation, not recommended in severe gastroparesis, acute gallbladder disease counseling, acute kidney injury due to volume depletion counseling, and pulmonary aspiration during anesthesia/deep sedation.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-related claims are either unsupported by the provided label excerpts or are too general, and multiple specific adverse-event incidence percentages and trial serious adverse reaction rates are not supported. Some contraindication statements use “not recommended” language rather than the label’s “contraindicated” language, which could affect appropriate interpretation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Numerous adverse-event frequency and serious adverse reaction percentages, and several safety/restriction statements, are not supported by the provided label excerpts; contraindication language is imprecise.
Suggested Improvement
Restrict statements to those explicitly supported by the provided label text (e.g., use contraindication wording for MTC/MEN2 and hypersensitivity; cite severe GI reactions and severe gastroparesis recommendation/avoidance from the label; remove unsupported incidence percentages and unsupported restriction claims; align “contact physician” vs “immediate medical attention” with the label wording).